IXICO plc (IXI.L)

7,38 -0,25 (-3,28%) Alla chiusura: 04:10PM BST

IXICO plc

Griffin Court
4th Floor 15 Long Lane
London EC1A 9PN
United Kingdom
44 20 3763 7499
https://ixico.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 89

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Giulio Cerroni	CEO & Director	328k	N/D	1961
Mr. Grant Nash	CFO, Company Secretary & Executive Director	216k	N/D	N/D
Prof. Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Prof. Derek Lionel Glendon Hill	Co-Founder and President of Regulatory Science & External Relations	387,01k	N/D	1966
Prof. David Hawkes CPhys, FInstP, FIPEM, FREng, Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Prof. Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Mr. Mark Austin	Director of Technology	N/D	N/D	N/D
Dr. Robin Wolz	Chief Scientific Officer	N/D	N/D	N/D
Ms. Hannah Esfahanian	HR Manager	N/D	N/D	N/D
Dr. John Hall	Senior Vice President of Business Development	N/D	N/D	1979

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, the company focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, and orphan and rare diseases. Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di IXICO plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.